Nuventra Pharma Sciences is now Allucent. Learn more here.

Take a deeper dive

Webinar | Regulatory Pathways for Drugs, Devices, & Combination Products

This webinar covers regulatory pathways for drugs, devices, and combination products. Dr. Lamson provides his insights on the 505(b)(2) pathway for new drugs while Ms. Benokraitis discusses a variety of regulatory pathways for devices, including 510(k), Premarket Approval (PMA), and De Novo. The presentation concludes with a discussion of how these various regulatory pathways intersect for drug-device combination products.

At the end of this webinar, attendees should have a better understanding of:

  • How to use the 505(b)(2) pathway to streamline drug development effectively
  • Which device regulatory pathway is appropriate for your standalone device or combination product
  • The interplay of drug and device pathways for developing combination products

Meet the Presenters

Michael J. Lamson, Ph.D.
Vice President, Clinical Pharmacology & Pharmacokinetics | Nuventra

Dr. Lamson has over 28 years of experience in pharmacokinetics and clinical pharmacology. Dr. Lamson’s strategic regulatory experience includes product development for NDAs, sNDAs, ANDAs, and 505(b)(2) NDAs. His skills also include using innovative analytical methods, such as modeling and simulation, to evaluate PK disposition and in vivo drug delivery performance throughout drug development.

Kristin Benokraitis
Director of Quality & Operations | Gilero 

Ms. Benokraitis has over 17 years of experience working with medical and drug delivery devices. She began working at Gilero in 2007 as a Quality Engineer and became the Director of Quality and Operations in 2011. Kristin is the company’s regulatory subject matter expert, having authored multiple regulatory submissions. In addition, she has managed countless projects developing medical devices and combination products for a variety of clinical applications.

Explore Our Blog

How to Use Modeling and Simulation to Optimize a 505(b)(2) Application

A 505(b)(2) application is a hybrid of a full new drug application and an abbreviated new drug application. The terms…

Read More

FDA Project Optimus: Selecting the Optimal Dose for Oncology Therapeutics

Across the spectrum of therapeutic indications, typically, the majority of new investigational drugs are evaluated in randomized dose-ranging clinical trials.…

Read More

Benefits of Utilizing the 505(b)(2) Pathway for Prodrugs

Over the past decade, at least 30 prodrugs have been approved by the US Food and Drug Administration (FDA). It…

Read More